Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

James L.L. Tullis net worth and biography

James Tullis Biography and Net Worth

Director of Exagen

Jim Tullis founded Tullis Health Investors (“THI” or “Tullis-Dickerson & Co., Inc.”) in 1986 and has a career of over 40 years in health care investing. Prior to establishing Tullis Health Investors, Jim was a Senior Vice President of E.F. Hutton & Co. (1983-1986) and a Principal at Morgan Stanley & Co. (1974-1983), where he led health care investment research and, later, healthcare investment banking. During his tenure at Morgan Stanley, he received recognition 14 times on the Institutional Investor All-Star list of Wall Street’s top securities analysts and listing as a top home run hitter. He was twice named #1 Drug Analyst and was featured on the Wall Street Week television program. From 1972-1974, Jim was Vice President of Putnam Funds researching health care industry equities. Under Jim’s direction, THI has managed several venture capital funds investing into the health care industry. Winning portfolio companies of those funds include Adams Respiratory and Sirion (with innovative concepts in pharmaceuticals); Synageva and BioRexis (biotechnology); Atritech and Vidacare (medical devices); PSS World Medical and Impulse Monitoring (medical services); and Intelliclaim and QuadraMed (health care information technology). Jim is a graduate of Stanford University and earned an MBA from Harvard Business School. He currently sits on the Boards of the Lord Abbett family of mutual funds, Crane Corporation (NYSE: CR), SupplyPro, Inc., Exagen Inc., and electroCore, LLC.

What is James L.L. Tullis' net worth?: The estimated net worth of James L.L. Tullis is at least $2.17 million as of June 15th, 2023. Tullis owns 1,515,839 shares of Exagen stock worth more than $2,165,982 as of April 18th. This net worth approximation does not reflect any other assets that Tullis may own. Learn More about James L.L. Tullis' net worth.
How do I contact James L.L. Tullis?: The corporate mailing address for Tullis and other Exagen executives is 1261 Liberty Way Suite C, VISTA CA, 92081. Exagen can also be reached via phone at 760-560-1501 and via email at [email protected]. Learn More on James L.L. Tullis' contact information.
Has James L.L. Tullis been buying or selling shares of Exagen?: James L.L. Tullis has not been actively trading shares of Exagen during the last ninety days. Most recently, on Thursday, June 15th, James L. L Tullis bought 167 shares of Exagen stock. The stock was acquired at an average cost of $3.11 per share, with a total value of $519.37. Following the completion of the transaction, the insider now directly owns 1,515,839 shares of the company's stock, valued at $4,714,259.29. Learn More on James L.L. Tullis' trading history.
Who are Exagen's active insiders?: Exagen's insider roster includes Wendy Johnson (Director), and James Tullis (Director). Learn More on Exagen's active insiders.
Are insiders buying or selling shares of Exagen?: In the last year, Exagen insiders bought shares 1 times. They purchased a total of 167 shares worth more than $519.37. In the last year, insiders at the sold shares 2 times. They sold a total of 46,603 shares worth more than $83,600.69. The most recent insider tranaction occured on March, 4th when CFO Kamal Adawi sold 12,784 shares worth more than $24,417.44. Insiders at Exagen own 36.8% of the company. Learn More about insider trades at Exagen.
Information on this page was last updated on 3/4/2024.

James L.L. Tullis Insider Trading History at Exagen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/15/2023	Buy	167	$3.11	$519.37	1,515,839
8/4/2021	Sell	2,100	$11.39	$23,919.00	21,348
8/2/2021	Sell	1,800	$11.92	$21,456.00
6/28/2021	Sell	10,858	$14.98	$162,652.84	21,348
6/25/2021	Sell	8,763	$16.03	$140,470.89	21,348
2/5/2021	Sell	3,000	$17.00	$51,000.00	21,348
1/19/2021	Sell	257	$15.56	$3,998.92	24,605
1/15/2021	Sell	1,014	$15.51	$15,727.14	24,605
1/13/2021	Sell	5,729	$15.63	$89,544.27	29,619
12/15/2020	Sell	12,000	$12.23	$146,760.00	31,348
12/10/2020	Sell	10,000	$14.03	$140,300.00	31,348
11/9/2020	Sell	882	$16.21	$14,297.22	31,348
10/19/2020	Sell	6,618	$15.35	$101,586.30	34,429
10/15/2020	Sell	4,316	$14.88	$64,222.08	34,429
9/11/2020	Sell	15,000	$12.40	$186,000.00	38,745
8/18/2020	Sell	14,987	$16.61	$248,934.07	38,745
8/14/2020	Sell	1,398	$16.95	$23,696.10	38,745
6/9/2020	Sell	578	$12.77	$7,381.06	40,143
5/27/2020	Sell	605	$12.57	$7,604.85	41,569

James L.L. Tullis Buying and Selling Activity at Exagen

Exagen Company Overview

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.

Today's Range

Now: $1.43

$1.36

$1.45

50 Day Range

MA: $1.77

$1.40

$2.25

2 Week Range

Now: $1.43

$1.30

$3.92

Volume

8,492 shs

Average Volume

40,765 shs

Market Capitalization

$24.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

The “Perfect Storm” for Gold

From Gold Safe Exchange | Ad